MaxCyte Stock

MaxCyte EV/EBIT

Delisted

The EV/EBIT (Enterprise Value to EBIT) of MaxCyte (MXCT) as of Jul 20, 2026 is -1.50. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -1.59 — a change of -5.66% (higher).

EV/EBIT

-1.50

YoY

-5.66%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of MaxCyte is 2026 -1.50 . EV/EBIT (Enterprise Value to EBIT) of MaxCyte was 2025 -1.59 . It decreases by -5.66% higher compared to the previous year.

The MaxCyte EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
0.00 base
Jan 1, 2020
0.00 base
Jan 1, 2021
-50.77 base
Jan 1, 2022
-20.30 base
Jan 1, 2023
-10.05 base
Jan 1, 2024
-0.12 base
Jan 1, 2025 (e)
-0.04 base
Jan 1, 2026 (e)
-0.04 base
YEARPRICE-TO-EBIT
2026 est -0.04
2025 est -0.04
2024 -0.12
2023 -10.05
2022 -20.30
2021 -50.77
2020 -
2019 -
2018 -
2017 -
2016 -
2015 -
2014 -
2013 -
2012 -
Access this data via the Eulerpool API
Get Free API Key

MaxCyte Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides MaxCyte's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates MaxCyte's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots MaxCyte's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if MaxCyte grows earnings faster than its peers.

MaxCyte Stock analysis

What does MaxCyte do? MaxCyte Inc is a US biotechnology company specializing in the development of platform-based technologies for the next generation of gene and cell therapies. They offer integrated platform technology for drug manufacturing, research, and development. Their proprietary platform technology, Flow ElectroporationTM, allows for efficient transduction of a variety of cells, making it a valuable tool for the production of CAR-T cell therapies. They also offer services for lentiviral production and customized gene therapy production. MaxCyte has secured $50 million in funding for expansion and has formed important partnerships in the industry. They are a leading player in the development of innovative technologies for gene and cell therapy products. MaxCyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MaxCyte stock

EV/EBIT (Enterprise Value to EBIT) of MaxCyte is -1.50 in 2026.

Access this data via the Eulerpool API
Get Free API Key

Valuation — MaxCyte

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — MaxCyte